Links for fulltext
     (May Require Subscription)
Supplementary

Article: Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63

TitleSerological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63
Authors
Issue Date2005
PublisherAmerican Society for Microbiology.
Citation
Clinical And Diagnostic Laboratory Immunology, 2005, v. 12 n. 11, p. 1317-1321 How to Cite?
AbstractThe serological response profile of severe acute respiratory syndrome (SARS) coronavirus (CoV) infection was defined by neutralization tests and subclass-specific immunofluorescent (IF) tests using serial sera from 20 patients. SARS CoV total immunoglobulin (Ig) (IgG, IgA, and IgM [IgGAM]) was the first antibody to be detectable. There was no difference in time to seroconversion between the patients who survived (n = 14) and those who died (n = 6). Although SARS CoV IgM was still detectable by IF tests with 8 of 11 patients at 7 months postinfection, the geometric mean titers dropped from 282 at 1 month postinfection to 19 at 7 months (P = 0.001). In contrast, neutralizing antibody and SARS CoV IgGAM and IgG antibody titers remained stable over this period. The SARS CoV antibody response was sometimes associated with an increase in preexisting IF IgG antibody titers for human coronaviruses OC43, 229E, and NL63. There was no change in IF IgG titer for virus capsid antigen from the herpesvirus that was used as an unrelated control, Epstein-Barr virus. In contrast, patients who had OC43 infections, and probably also 229E infections, without prior exposure to SARS CoV had increases of antibodies specific for the infecting virus but not for SARS CoV. There is a need for awareness of cross-reactive antibody responses between coronaviruses when interpreting IF serology. Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Persistent Identifierhttp://hdl.handle.net/10722/49172
ISSN
2007 Impact Factor: 2.511
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, KHen_HK
dc.contributor.authorCheng, VCCen_HK
dc.contributor.authorWoo, PCYen_HK
dc.contributor.authorLau, SKPen_HK
dc.contributor.authorPoon, LLMen_HK
dc.contributor.authorGuan, Yen_HK
dc.contributor.authorSeto, WHen_HK
dc.contributor.authorYuen, KYen_HK
dc.contributor.authorPeiris, JSMen_HK
dc.date.accessioned2008-06-12T06:36:02Z-
dc.date.available2008-06-12T06:36:02Z-
dc.date.issued2005en_HK
dc.identifier.citationClinical And Diagnostic Laboratory Immunology, 2005, v. 12 n. 11, p. 1317-1321en_HK
dc.identifier.issn1071-412Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/49172-
dc.description.abstractThe serological response profile of severe acute respiratory syndrome (SARS) coronavirus (CoV) infection was defined by neutralization tests and subclass-specific immunofluorescent (IF) tests using serial sera from 20 patients. SARS CoV total immunoglobulin (Ig) (IgG, IgA, and IgM [IgGAM]) was the first antibody to be detectable. There was no difference in time to seroconversion between the patients who survived (n = 14) and those who died (n = 6). Although SARS CoV IgM was still detectable by IF tests with 8 of 11 patients at 7 months postinfection, the geometric mean titers dropped from 282 at 1 month postinfection to 19 at 7 months (P = 0.001). In contrast, neutralizing antibody and SARS CoV IgGAM and IgG antibody titers remained stable over this period. The SARS CoV antibody response was sometimes associated with an increase in preexisting IF IgG antibody titers for human coronaviruses OC43, 229E, and NL63. There was no change in IF IgG titer for virus capsid antigen from the herpesvirus that was used as an unrelated control, Epstein-Barr virus. In contrast, patients who had OC43 infections, and probably also 229E infections, without prior exposure to SARS CoV had increases of antibodies specific for the infecting virus but not for SARS CoV. There is a need for awareness of cross-reactive antibody responses between coronaviruses when interpreting IF serology. Copyright © 2005, American Society for Microbiology. All Rights Reserved.en_HK
dc.format.extent388 bytes-
dc.format.mimetypetext/html-
dc.languageengen_HK
dc.publisherAmerican Society for Microbiology.en_HK
dc.relation.ispartofClinical and Diagnostic Laboratory Immunologyen_HK
dc.rightsClinical and Diagnostic Laboratory Immunology. Copyright © American Society for Microbiology.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsCopyright © American Society for Microbiology, Clinical and Diagnostic Laboratory Immunology, 2005, v. 12 n. 11, p. 1317-1321en_HK
dc.subject.meshAntibodies, Viral - blooden_HK
dc.subject.meshCoronavirus 229E, Human - immunologyen_HK
dc.subject.meshCoronavirus OC43, Human - immunologyen_HK
dc.subject.meshSARS Virus - immunologyen_HK
dc.subject.meshSevere Acute Respiratory Syndrome - blood - immunologyen_HK
dc.titleSerological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63en_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1071-412X&volume=12&issue=11&spage=1317&epage=1321&date=2005&atitle=Serological+responses+in+patients+with+severe+acute+respiratory+syndrome+coronavirus+infection+and+cross-reactivity+with+human+coronaviruses+229E,+OC43,+and+NL63en_HK
dc.identifier.emailWoo, PCY:pcywoo@hkucc.hku.hken_HK
dc.identifier.emailLau, SKP:skplau@hkucc.hku.hken_HK
dc.identifier.emailPoon, LLM:llmpoon@hkucc.hku.hken_HK
dc.identifier.emailGuan, Y:yguan@hkucc.hku.hken_HK
dc.identifier.emailYuen, KY:kyyuen@hkucc.hku.hken_HK
dc.identifier.emailPeiris, JSM:malik@hkucc.hku.hken_HK
dc.identifier.authorityWoo, PCY=rp00430en_HK
dc.identifier.authorityLau, SKP=rp00486en_HK
dc.identifier.authorityPoon, LLM=rp00484en_HK
dc.identifier.authorityGuan, Y=rp00397en_HK
dc.identifier.authorityYuen, KY=rp00366en_HK
dc.identifier.authorityPeiris, JSM=rp00410en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1128/CDLI.12.11.1317-1321.2005en_HK
dc.identifier.pmid16275947-
dc.identifier.pmcidPMC1287763en_HK
dc.identifier.scopuseid_2-s2.0-27744442003en_HK
dc.identifier.hkuros114690-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-27744442003&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume12en_HK
dc.identifier.issue11en_HK
dc.identifier.spage1317en_HK
dc.identifier.epage1321en_HK
dc.identifier.isiWOS:000233231500010-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChan, KH=35338760600en_HK
dc.identifier.scopusauthoridCheng, VCC=23670479400en_HK
dc.identifier.scopusauthoridWoo, PCY=7201801340en_HK
dc.identifier.scopusauthoridLau, SKP=7401596211en_HK
dc.identifier.scopusauthoridPoon, LLM=7005441747en_HK
dc.identifier.scopusauthoridGuan, Y=7202924055en_HK
dc.identifier.scopusauthoridSeto, WH=7005799377en_HK
dc.identifier.scopusauthoridYuen, KY=36078079100en_HK
dc.identifier.scopusauthoridPeiris, JSM=7005486823en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats